

#12 / Amdt. A  
5/31/02

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231.

CM  
10-15-01October 15, 2001  
DateS. Sheridan  
Sharon Sheridan

## PATENT APPLICATION

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tony N. Frudakis et al.  
Application No. : 09/590,583  
Filed : June 8, 2000  
For : COMPOSITIONS AND METHODS FOR THE THERAPY AND  
DIAGNOSIS OF BREAST CANCER

Examiner : A. Spiegler  
Art Unit : 1656  
Docket No. : 210121.419C9  
Date : October 15, 2001

Commissioner for Patents  
Washington, DC 20231

RESPONSE TO RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

Commissioner for Patents:

In response to the Restriction Requirement dated August 15, 2001, please extend the period of time for response one month, to expire on October 15, 2001. Enclosed are a Petition for an Extension of Time and the requisite fee.

Applicants hereby elect Group I, claims 4-7, 16, 58-60, and SEQ ID NO:307.

Prior to examination on the merits, kindly enter the following amendment:

In the Claims:

Please cancel claims 7, 58, and 59.

Please amend claims 4, 5, 6, 16 and 60 to read as follows:

4. (Amended) An isolated polynucleotide encoding at least 15 amino acid residues of a breast tumor protein, wherein the tumor protein comprises an amino acid sequence that is encoded by a polynucleotide comprising SEQ ID NO:307 or a complement of said sequence.

CORIXA 10/16/01  
CC: GSK